Activation of the NAD⁺–Sirtuin Axis Protects Against Chronic Doxorubicin-Induced Subclinical Renal Tubular Injury Through Restoration of…

Verdict. We investigated whether chronic low-dose DOX exposure induces persistent mitochondrial dysfunction in renal tubules and evaluated the therapeutic potential of activating the NAD⁺–Sirtuin axis. It intersects mitochondrial stress/dysfunction themes (mitochondrial dysfunction; functional impairment; oxidative stress).

What the authors report

Background and purpose Anthracyclines, such as doxorubicin (DOX), are associated with late-onset kidney dysfunction; however, the mechanisms underlying chronic tubular injury remain poorly understood. Experimental Approach C57BL/6 mice were repeatedly administered low-dose DOX with or without resveratrol (RSV) or nicotinamide mononucleotide (NMN), a sirtuin activator.

Key results stated in the abstract include the following. We investigated whether chronic low-dose DOX exposure induces persistent mitochondrial dysfunction in renal tubules and evaluated the therapeutic potential of activating the NAD⁺–Sirtuin axis. Key Results Chronic DOX administration induced tubular injury, despite preserving serum creatinine levels. SIM revealed mitochondrial fragmentation in tubular epithelial cells, whereas the Seahorse assay showed impaired mitochondrial respiratory capacity in isolated renal tubules.

Why it matters for mitochondrial biology

Within mitochondrial research, this work maps primarily to redox biology, metabolism, immunology, cancer. It is relevant to mitochondrial dysfunction discourse because the abstract invokes mitochondrial dysfunction, functional impairment, oxidative stress, inflammation. That does not by itself establish a validated disease mechanism; it indicates thematic proximity. Because a therapeutic or interventional angle is present, the piece is of interest for mitochondrial-targeted drug hypothesis generation—subject to full-text validation of endpoints and safety context. Server: biorxiv. Posted 2026-08-03. Synthesis confidence is bounded by abstract completeness.

Study design (abstract-level)

Experimental Approach C57BL/6 mice were repeatedly administered low-dose DOX with or without resveratrol (RSV) or nicotinamide mononucleotide (NMN), a sirtuin activator. Integrated proteomic and RNA sequencing analyses were performed to identify molecular alterations. SIM revealed mitochondrial fragmentation in tubular epithelial cells, whereas the Seahorse assay showed impaired mitochondrial respiratory capacity in isolated renal tubules.

Principal findings

1. We investigated whether chronic low-dose DOX exposure induces persistent mitochondrial dysfunction in renal tubules and evaluated the therapeutic potential of activating the NAD⁺–Sirtuin axis.
2. Key Results Chronic DOX administration induced tubular injury, despite preserving serum creatinine levels.
3. SIM revealed mitochondrial fragmentation in tubular epithelial cells, whereas the Seahorse assay showed impaired mitochondrial respiratory capacity in isolated renal tubules.
4. Importantly, both RSV and NMN attenuated tubular injury, restored mitochondrial metabolic pathways, reduced SOD2 acetylation, improved mitochondrial morphology, and suppressed inflammatory responses.
5. These findings identify mitochondrial dysfunction as a central therapeutic target in DOX-induced nephrotoxicity and support sirtuin modulation as a potential strategy for preventing chemotherapy-related chronic kidney injury.

Limitations of this brief

• This Mitos brief is an abstract-level synthesis of a preprint; it is not peer review and not a substitute for reading the full paper.
• Preprint status: findings may change with revision or journal review.
• Effect sizes, n numbers, statistics, and full experimental controls are typically incomplete at abstract resolution.
• Comparator/control language is weak or absent in the abstract, limiting causal inference from this brief alone.
• Primary source: biorxiv DOI 10.64898/2026.07.29.741470 (posted 2026-08-03).

Open scientific questions

• Which specific experimental panels in the full paper establish the strongest causal claim, and how robust are the controls?
• Are OXPHOS defects primary drivers or secondary consequences of broader cellular stress?
• What dose, timing, and off-target profile would be required to take the intervention seriously as a therapeutic hypothesis?
• How do these findings sit relative to prior literature on the same pathway—replication, contradiction, or incremental extension?

Bottom line

For mitochondrial biologists focused on redox biology, metabolism, immunology, this preprint is worth full-text review soon. Abstract-level takeaway: We investigated whether chronic low-dose DOX exposure induces persistent mitochondrial dysfunction in renal tubules and evaluated the therapeutic potential of activating the NAD⁺–Sirtuin axis. Confirm methods, effect sizes, and controls in the full PDF before citing the result as established.

Bibliographic record

Abstract-based editorial synthesis by Mitos. Not peer review.